Upcoming Conference Calls, Commencement of Shipments, Stock Price Movements, Awareness Campaigns, and Acquisitions - Analyst Notes on Incyte, Impax, ANI, Ironwood and Aastrom

NEW YORK, April 24, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), Impax Laboratories Inc. (NASDAQ: IPXL), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) and Aastrom Biosciences, Inc. (NASDAQ: ASTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1519-100free.

Incyte Corporation Analyst Notes
On April 16, 2014, Incyte Corp. (Incyte) announced that it will report its Q1 2014 financial results through a press release on Thursday, May 1, 2014, at 7:00 a.m. ET. The Company informed that it will also host a conference call on the same day at 8:30 a.m. ET. Incyte stated that the live webcast of the call will be accessible through the Investor Relations section of the Company's website. The full analyst notes on Incyte are available to download free of charge at:

http://www.analystsreview.com/1519-INCY-24Apr2014.pdf

Impax Laboratories Inc. Analyst Notes
On April 16, 2014, Impax Laboratories, Inc. (Impax) announced that it intends to begin the shipment of authorized generic RENVELA (sevelamer carbonate 800 mg tablets), through Global Pharmaceuticals, Impax's generics division. Under the terms of a settlement agreement between Genzyme and Impax, Genzyme agreed to grant Impax a license to sell an allotment of a specified number of bottles of an authorized generic version of RENVELA tablets commencing on April 16, 2014. "We are excited to market this product and provide patients with a more affordable treatment option," said Carole S. Ben-Maimon, M.D., President of Global Pharmaceuticals. "This product will be an important contributor to our 2014 financial results." The Company added that it continues to pursue approval of its pending Abbreviated New Drug Application for generic RENVELA with the U.S. Food and Drug Administration (FDA). The full analyst notes on Impax are available to download free of charge at:

http://www.analystsreview.com/1519-IPXL-24Apr2014.pdf

ANI Pharmaceuticals, Inc. Analyst Notes
On April 21, 2014, ANI Pharmaceuticals Inc. (ANI) stock increased 20.67% to end the day at $30.83. The Company's stock rose 42.60% over the past three trading days, compared to the Nasdaq Composite which gained 2.17% during the same trading period. The full analyst notes on ANI are available to download free of charge at:

http://www.analystsreview.com/1519-ANIP-24Apr2014.pdf

Ironwood Pharmaceuticals Inc. Analyst Notes
On April 10, 2014, Ironwood Pharmaceuticals, Inc. (Ironwood) and Forest Laboratories, Inc. (Forest) announced the launch of a new direct-to-consumer (DTC) patient awareness campaign for LINZESS, a once-daily treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). According to the Company, the campaign's goal is to help adults recognize the symptoms of these disorders and ask their doctor about LINZESS to help proactively manage their disease. Tom McCourt, Chief Commercial Officer at Ironwood said, "Even among patients who are diagnosed with IBS-C or CIC, fewer than 10 percent are aware of LINZESS, so we see a significant need to raise awareness of these disease states and of LINZESS as a possible treatment option." According to the Company, LINZESS is the first and only FDA-approved treatment in a new class of medicines for IBS-C and CIC known as GC-C agonists. The full analyst notes on Ironwood are available to download free of charge at:

http://www.analystsreview.com/1519-IRWD-24Apr2014.pdf

Aastrom Biosciences, Inc. Analyst Notes
On April 21, 2014, Aastrom Biosciences, Inc. (Aastrom) announced that it has entered into a definitive agreement to acquire Cell Therapy and Regenerative Medicine (CTRM) business of Sanofi for $6.5 million. "The acquisition of Sanofi's CTRM business is a transformative transaction that positions Aastrom as a fully-integrated global regenerative medicine company," said Nick Colangelo, President and CEO of Aastrom. "The CTRM business brings us global manufacturing, marketing and sales capabilities that are structured to support the current portfolio of marketed products as well as our future product development plans. This transaction also provides us with a platform to generate operating income to support the development of our high-potential pipeline products and continued growth through additional strategic transactions." The Company stated that acquisition is subject to customary closing conditions and it intends to close it in approximately three weeks from the date of announcement. The full analyst notes on Aastrom are available to download free of charge at:

http://www.analystsreview.com/1519-ASTM-24Apr2014.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review